-
1
-
-
7244239275
-
Skeletal complications in men with prostate cancer: Effects on quality-of-life outcomes throughout the continuum of care
-
Crawford ED. Skeletal complications in men with prostate cancer: effects on quality-of-life outcomes throughout the continuum of care. Eur Urol 2004;3:10-5.
-
(2004)
Eur Urol
, vol.3
, pp. 10-15
-
-
Crawford, E.D.1
-
2
-
-
33644666787
-
Bisphosphonates for treatment and prevention of bone metastases
-
Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 2005;23:8219-24.
-
(2005)
J Clin Oncol
, vol.23
, pp. 8219-8224
-
-
Michaelson, M.D.1
Smith, M.R.2
-
3
-
-
33646444443
-
Bisphosphonates for malignancy-related bone disease: Current status, future developments
-
Body JJ. Bisphosphonates for malignancy-related bone disease: current status, future developments. Support Care Cancer 2006;14:408-18.
-
(2006)
Support Care Cancer
, vol.14
, pp. 408-418
-
-
Body, J.J.1
-
4
-
-
0037009822
-
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
-
Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68.
-
(2002)
J Natl Cancer Inst
, vol.94
, pp. 1458-1468
-
-
Saad, F.1
Gleason, D.M.2
Murray, R.3
-
5
-
-
2942518111
-
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
-
Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82.
-
(2004)
J Natl Cancer Inst
, vol.96
, pp. 879-882
-
-
Saad, F.1
Gleason, D.M.2
Murray, R.3
-
7
-
-
0036901126
-
Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis
-
Green JR, Cleza rdin P. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 2002;25:S3-9.
-
(2002)
Am J Clin Oncol
, vol.25
-
-
Green, J.R.1
Cleza rdin, P.2
-
9
-
-
0029898894
-
Protein prenylation: Molecular mechanisms and functional consequences
-
Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996;65:241-69.
-
(1996)
Annu Rev Biochem
, vol.65
, pp. 241-269
-
-
Zhang, F.L.1
Casey, P.J.2
-
10
-
-
5444242637
-
Bisphosphonates: Preclinical review
-
Green JR. Bisphosphonates: preclinical review. Oncologist 2004;9 Suppl 4:3-13.
-
(2004)
Oncologist
, vol.9
, Issue.SUPPL. 4
, pp. 3-13
-
-
Green, J.R.1
-
11
-
-
20444486612
-
Bisphosphonates and cancer-induced bone disease: Beyond their antiresorptive activity
-
Clezardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 2005;65:4971-4.
-
(2005)
Cancer Res
, vol.65
, pp. 4971-4974
-
-
Clezardin, P.1
Ebetino, F.H.2
Fournier, P.G.3
-
12
-
-
28644440158
-
Histone deacetylase inhibitors: Discovery and development as anticancer agents
-
Marks PA, Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 2005;14:1497-511.
-
(2005)
Expert Opin Investig Drugs
, vol.14
, pp. 1497-1511
-
-
Marks, P.A.1
Dokmanovic, M.2
-
13
-
-
13844309711
-
Clinical development of histone deacetylase inhibitors as anticancer agents
-
Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005;45:495-528.
-
(2005)
Annu Rev Pharmacol Toxicol
, vol.45
, pp. 495-528
-
-
Drummond, D.C.1
Noble, C.O.2
Kirpotin, D.B.3
Guo, Z.4
Scott, G.K.5
Benz, C.C.6
-
15
-
-
33846122993
-
Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug
-
Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007;25:84-90.
-
(2007)
Nat Biotechnol
, vol.25
, pp. 84-90
-
-
Marks, P.A.1
Breslow, R.2
-
16
-
-
33748794547
-
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
-
Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-681.
-
(2006)
Pharmacol Rev
, vol.58
, pp. 621-681
-
-
Chou, T.C.1
-
18
-
-
0042090495
-
Novel mechanisms of apoptosis induced by histone deacetylase inhibitors
-
Peart MJ, Tainton KM, Ruefli AA, et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003;63:4460-71.
-
(2003)
Cancer Res
, vol.63
, pp. 4460-4471
-
-
Peart, M.J.1
Tainton, K.M.2
Ruefli, A.A.3
-
19
-
-
33845910925
-
Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status
-
Ory B, Blanchard F, Battaglia S, Gouin F, Redini F, Heymann D. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol 2007;71:333-43.
-
(2007)
Mol Pharmacol
, vol.71
, pp. 333-343
-
-
Ory, B.1
Blanchard, F.2
Battaglia, S.3
Gouin, F.4
Redini, F.5
Heymann, D.6
-
20
-
-
0031589542
-
Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation
-
Crick DC, Andres DA, Waechter CJ. Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation. Biochem Biophys Res Commun 1997;237:483-7.
-
(1997)
Biochem Biophys Res Commun
, vol.237
, pp. 483-487
-
-
Crick, D.C.1
Andres, D.A.2
Waechter, C.J.3
-
21
-
-
0028973293
-
Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes
-
Lerner EC, Qian Y, Blaskovich MA, et al. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 1995;270:26802-6.
-
(1995)
J Biol Chem
, vol.270
, pp. 26802-26806
-
-
Lerner, E.C.1
Qian, Y.2
Blaskovich, M.A.3
-
22
-
-
0029926493
-
Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation
-
McGuire TF, Qian Y, Vogt A, Hamilton AD, Sebti SM. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation. J Biol Chem 1996;271:27402-7.
-
(1996)
J Biol Chem
, vol.271
, pp. 27402-27407
-
-
McGuire, T.F.1
Qian, Y.2
Vogt, A.3
Hamilton, A.D.4
Sebti, S.M.5
-
23
-
-
33845944650
-
Multilevel modulation of the mevalonate and protein-prenylation circuitries as a novel strategy for anticancer therapy
-
Konstantinopoulos PA, Papavassiliou AG. Multilevel modulation of the mevalonate and protein-prenylation circuitries as a novel strategy for anticancer therapy. Trends Pharmacol Sci 2007;28:6-13.
-
(2007)
Trends Pharmacol Sci
, vol.28
, pp. 6-13
-
-
Konstantinopoulos, P.A.1
Papavassiliou, A.G.2
-
24
-
-
0034932935
-
The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro
-
Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 2001;12:459-65.
-
(2001)
Anticancer Drugs
, vol.12
, pp. 459-465
-
-
Sonnemann, J.1
Eckervogt, V.2
Truckenbrod, B.3
Boos, J.4
Winkelmann, W.5
van Valen, F.6
-
25
-
-
0141455522
-
Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis
-
Evdokiou A, Labrinidis A, Bouralexis S, Hay S, Findlay DM. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone 2003;33:216-28.
-
(2003)
Bone
, vol.33
, pp. 216-228
-
-
Evdokiou, A.1
Labrinidis, A.2
Bouralexis, S.3
Hay, S.4
Findlay, D.M.5
-
26
-
-
0242319830
-
The bisphosphonate pamidronate is a potent inhibitor of Ewing's sarcoma cell growth in vitro
-
Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F. The bisphosphonate pamidronate is a potent inhibitor of Ewing's sarcoma cell growth in vitro. Anticancer Drugs 2003;14:767-71.
-
(2003)
Anticancer Drugs
, vol.14
, pp. 767-771
-
-
Sonnemann, J.1
Eckervogt, V.2
Truckenbrod, B.3
Boos, J.4
Winkelmann, W.5
van Valen, F.6
-
27
-
-
0030931858
-
Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity
-
Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997;98:665-72.
-
(1997)
Br J Haematol
, vol.98
, pp. 665-672
-
-
Shipman, C.M.1
Rogers, M.J.2
Apperley, J.F.3
Russell, R.G.4
Croucher, P.I.5
-
28
-
-
33750367958
-
Antitumor effects of amino-bisphosphonates on renal cell carcinoma cell lines
-
Pandha H, Birchall L, Meyer B, et al. Antitumor effects of amino-bisphosphonates on renal cell carcinoma cell lines. J Urol 2006;176:2255-61.
-
(2006)
J Urol
, vol.176
, pp. 2255-2261
-
-
Pandha, H.1
Birchall, L.2
Meyer, B.3
-
29
-
-
10444274954
-
Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anticancer agents against small cell lung cancer cell lines
-
Matsumoto S, Kimura S, Segawa H, et al. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anticancer agents against small cell lung cancer cell lines. Lung Cancer 2005;47:31-9.
-
(2005)
Lung Cancer
, vol.47
, pp. 31-39
-
-
Matsumoto, S.1
Kimura, S.2
Segawa, H.3
-
30
-
-
0034107048
-
Bisphosphonates induce apoptosis in human breast cancer cell lines
-
Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459-68.
-
(2000)
Br J Cancer
, vol.82
, pp. 1459-1468
-
-
Senaratne, S.G.1
Pirianov, G.2
Mansi, J.L.3
Arnett, T.R.4
Colston, K.W.5
-
31
-
-
0033783227
-
Bisphosphonates induce breast cancer cell death in vitro
-
Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000;15:2211-21.
-
(2000)
J Bone Miner Res
, vol.15
, pp. 2211-2221
-
-
Fromigue, O.1
Lagneaux, L.2
Body, J.J.3
-
32
-
-
0035866791
-
Bisphosphonate treatment inhibits the growth of prostate cancer cells
-
Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001;61:2602-8.
-
(2001)
Cancer Res
, vol.61
, pp. 2602-2608
-
-
Lee, M.V.1
Fong, E.M.2
Singer, F.R.3
Guenette, R.S.4
-
33
-
-
0037236978
-
Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer
-
Corey E, Brown LG, Quinn JE, et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003;9:295-306.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 295-306
-
-
Corey, E.1
Brown, L.G.2
Quinn, J.E.3
-
34
-
-
0037664952
-
Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells
-
Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 2003;170:246-52.
-
(2003)
J Urol
, vol.170
, pp. 246-252
-
-
Oades, G.M.1
Senaratne, S.G.2
Clarke, I.A.3
Kirby, R.S.4
Colston, K.W.5
-
35
-
-
3242771333
-
Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation
-
Coxon JP, Oades GM, Kirby RS, Colston KW. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 2004;94:164-70.
-
(2004)
BJU Int
, vol.94
, pp. 164-170
-
-
Coxon, J.P.1
Oades, G.M.2
Kirby, R.S.3
Colston, K.W.4
-
36
-
-
0043075946
-
Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines
-
Witters LM, Crispino J, Fraterrigo T, Green J, Lipton A. Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol 2003;26:S92-7.
-
(2003)
Am J Clin Oncol
, vol.26
-
-
Witters, L.M.1
Crispino, J.2
Fraterrigo, T.3
Green, J.4
Lipton, A.5
-
37
-
-
0141790853
-
The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph + leukemia activity of imatinib mesylate
-
Kuroda J, Kimura S, Segawa H, et al. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph + leukemia activity of imatinib mesylate. Blood 2003;102:2229-35.
-
(2003)
Blood
, vol.102
, pp. 2229-2235
-
-
Kuroda, J.1
Kimura, S.2
Segawa, H.3
-
38
-
-
11144254409
-
Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells
-
Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005;113:364-71.
-
(2005)
Int J Cancer
, vol.113
, pp. 364-371
-
-
Neville-Webbe, H.L.1
Rostami-Hodjegan, A.2
Evans, C.A.3
Coleman, R.E.4
Holen, I.5
-
39
-
-
20544442197
-
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma
-
Heymann D, Ory B, Blanchard F, et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 2005;37:74-86.
-
(2005)
Bone
, vol.37
, pp. 74-86
-
-
Heymann, D.1
Ory, B.2
Blanchard, F.3
-
40
-
-
32044447160
-
Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment
-
Brubaker KD, Brown LG, Vessella RL, Corey E. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 2006;6:15.
-
(2006)
BMC Cancer
, vol.6
, pp. 15
-
-
Brubaker, K.D.1
Brown, L.G.2
Vessella, R.L.3
Corey, E.4
-
41
-
-
33846523379
-
Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma
-
Horie N, Murata H, Kimura S, et al. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma. Br J Cancer 2007;96:255-61.
-
(2007)
Br J Cancer
, vol.96
, pp. 255-261
-
-
Horie, N.1
Murata, H.2
Kimura, S.3
-
42
-
-
34047129164
-
Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells
-
Benassi MS, Chiechi A, Ponticelli F, et al. Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Lett 2007;250:194-205.
-
(2007)
Cancer Lett
, vol.250
, pp. 194-205
-
-
Benassi, M.S.1
Chiechi, A.2
Ponticelli, F.3
-
43
-
-
0037169358
-
Apoptosis: A link between cancer genetics and chemotherapy
-
Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
-
(2002)
Cell
, vol.108
, pp. 153-164
-
-
Johnstone, R.W.1
Ruefli, A.A.2
Lowe, S.W.3
-
44
-
-
33645638181
-
Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells
-
Goffinet M, Thoulouzan M, Pradines A, et al. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 2006;6:60.
-
(2006)
BMC Cancer
, vol.6
, pp. 60
-
-
Goffinet, M.1
Thoulouzan, M.2
Pradines, A.3
|